Herantis Pharma Plc.

HRTIS

Public Market Listing

HRTIS

Primary exchange listing

Live quotes, historical charts, and market capitalization for Herantis Pharma Plc. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
CDNFPeptide
Parkinson's Disease

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

7 October 2025Topline resultHER-096HER-096 Phase 1b (NCT06659562) in Parkinson's disease met all primary and secondary endpoints
Herantis Pharma Plc · Source ↗

Financial reports

No financial reports recorded.